LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Aandelen Lijst・Geron Corp

Geron Corp

Gesloten

SectorGezondheidszorg

1.45 -7.05

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.42

Max

1.56

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -29M
Verkoop	788K 48M
Winstmarge	-60.11
Werknemers	258
EBITDA	-14M -24M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+96.97% upside

Dividenden
By Dow Jones
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-124M 1B
Vorige openingsprijs	8.5
Vorige sluitingsprijs	1.45

Geron Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 mei 2026, 23:58 UTC

Winsten

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mei 2026, 22:57 UTC

Winsten

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mei 2026, 23:52 UTC

Winsten

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mei 2026, 23:45 UTC

Marktinformatie

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mei 2026, 23:39 UTC

Marktinformatie

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mei 2026, 23:28 UTC

Marktinformatie

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mei 2026, 23:11 UTC

Winsten

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mei 2026, 23:06 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mei 2026, 23:05 UTC

Winsten

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mei 2026, 23:04 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mei 2026, 23:03 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mei 2026, 23:03 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mei 2026, 23:02 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mei 2026, 23:00 UTC

Marktinformatie

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mei 2026, 22:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 mei 2026, 22:45 UTC

Marktinformatie

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mei 2026, 22:42 UTC

Winsten

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mei 2026, 22:33 UTC

Winsten

Acquisities, Fusies, Overnames

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mei 2026, 22:32 UTC

Winsten

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mei 2026, 22:31 UTC

Winsten

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mei 2026, 22:31 UTC

Winsten

Macquarie: 68% of FY Income From International >MQG.AU

7 mei 2026, 22:30 UTC

Winsten

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mei 2026, 22:30 UTC

Winsten

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mei 2026, 22:29 UTC

Winsten

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mei 2026, 22:28 UTC

Winsten

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mei 2026, 22:28 UTC

Winsten

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mei 2026, 22:27 UTC

Winsten

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mei 2026, 22:27 UTC

Winsten

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mei 2026, 22:26 UTC

Winsten

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mei 2026, 22:25 UTC

Winsten

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer Vergelijking

Prijswijziging

Geron Corp Prognose

Koersdoel

By TipRanks

96.97% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.25 USD 96.97%

Hoogste 5 USD

Laagste 1 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Geron Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Geron Corp - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.